161 related articles for article (PubMed ID: 36983070)
21. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
[TBL] [Abstract][Full Text] [Related]
22. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
23. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
[TBL] [Abstract][Full Text] [Related]
24. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Isham CR; Bossou AR; Negron V; Fisher KE; Kumar R; Marlow L; Lingle WL; Smallridge RC; Sherman EJ; Suman VJ; Copland JA; Bible KC
Sci Transl Med; 2013 Jan; 5(166):166ra3. PubMed ID: 23283368
[TBL] [Abstract][Full Text] [Related]
25. INHIBITOR OF THE TRANSCRIPTION FACTOR NF-κB, DHMEQ, ENHANCES THE EFFECT OF PACLITAXEL ON CELLS OF ANAPLASTIC THYROID CARCINOMA IN VITRO AND IN VIVO.
Pushkarev VV; Starenki DV; Pushkarev VM; Kovzun OI; Tronko MD
Ukr Biochem J; 2015; 87(3):63-74. PubMed ID: 26502701
[TBL] [Abstract][Full Text] [Related]
26. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
27. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
28. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
29. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
31. EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals.
Hao F; Zhu Q; Lu L; Sun S; Huang Y; Zhang J; Liu Z; Miao Y; Jiao X; Chen D
Oncol Res; 2020 Sep; 28(4):345-355. PubMed ID: 32138807
[TBL] [Abstract][Full Text] [Related]
32. Potent antitumor activity of novel taxoids in anaplastic thyroid cancer.
Wang M; Wang C; Feng C; Guo W; Chen H; Liu B; Li E; Liu W; Taouil A; Ojima I; Hou P
Endocrine; 2022 Feb; 75(2):465-477. PubMed ID: 34591230
[TBL] [Abstract][Full Text] [Related]
33. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
[TBL] [Abstract][Full Text] [Related]
34. Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR‑135a‑mediated c‑myc activation.
Wang Y; Hou Z; Li D
Mol Med Rep; 2018 Sep; 18(3):3068-3076. PubMed ID: 30015867
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.
Kocdor MA; Cengiz H; Ates H; Kocdor H
Anticancer Agents Med Chem; 2019; 19(15):1887-1898. PubMed ID: 31584382
[TBL] [Abstract][Full Text] [Related]
36. Effects of melatonin on the toxicity and proliferation of human anaplastic thyroid cancer cell line.
Ghorbani-Anarkooli M; Dabirian S; Zendedel A; Moladoust H; Bahadori MH
Acta Histochem; 2021 Apr; 123(3):151700. PubMed ID: 33667778
[TBL] [Abstract][Full Text] [Related]
37. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
[TBL] [Abstract][Full Text] [Related]
38. Biochemical effects of combined action of gamma-irradiation and paclitaxel on anaplastic thyroid cancer cells.
Pushkarev VM; Kovzun OI; Pushkarev VV; Tronko MD
Ukr Biokhim Zh (1999); 2013; 85(1):51-61. PubMed ID: 23534290
[TBL] [Abstract][Full Text] [Related]
39. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway.
Wang XM; Liu Y; Fan YX; Liu Z; Yuan QL; Jia M; Geng ZS; Gu L; Lu XB
Cancer Biol Ther; 2018 Jul; 19(7):590-597. PubMed ID: 29561707
[TBL] [Abstract][Full Text] [Related]
40. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]